Symrise AG Germany | Chemicals | MCap EUR 13,461m 11 March 2021 INITIATION Sustained sales and HOLD (na) Target price EUR 100.00 (none) Current price EUR 99.40 earnings growth, despite Up/downside 0.6% macro headwinds What’s it all about? Symrise reported reliable results in an exceptional year (2020), with a marginal miss in sales guidance amid the cyber-attack in late Q4 2020 and EBITDA in line. Organic sales growth is expected to accelerate this year, as pandemic-related headwinds are likely to ease and business activities have normalised following the cyber-attack. Moreover, mid-term targets seem achievable on an expanded portfolio and planned integration of MAIN AUTHOR the Flavor and Nutrition divisions, which may offer strong cross-selling opportunities. Thomas Wissler We initiate our coverage with a HOLD recommendation and a PT of EUR 100.00, based
[email protected] on our DCF model. +49 40 309 293-58 IMPORTANT. Please refer to the last page of this report for “Important disclosures” alsterresearch.com and analyst(s) certifications. This research is the product of AlsterResearch, which is authorized and regulated by the BaFin in Germany. AlsterResearch Page 2 of 19 Symrise AG Germany | Chemicals | MCap EUR 13,461m | EV EUR 15,468m MAIN AUTHOR HOLD (na) Target price EUR 100.00 (none) Current price EUR 99.40 Thomas Wissler Up/downside 0.6%
[email protected] +49 40 309 293-58 Sustained sales and earnings growth, despite macro headwinds Despite COVID-19-induced slippages in consumer demand across segments and cybersecurity attack in December 2020, Symrise continued to post healthy sales and earnings, given its highly differentiated business model.